tirzepatide fda indications is FDA-approved for weight management, with clinical trials showing average weight loss of 15–22.5% over 72 weeks. It's a prescription-only therapy, meaning it's not for everyone, and it works by acting tirzepatide from eli lilly Lilly's

Alruwaili H, Dehestani B, le Roux CW

NAC has earned special recognition for supporting respiratory health

TZP Suppresses Tumor Growth in Diabetic and Non-Diabetic Mouse Models To validate the in vitro findings in vivo, the study employed multiple murine colorectal cancer models, including orthotopic CRC implantation in T1DM mice (induced with streptozotocin, STZ) and subcutaneous CRC models in T2DM mice (induced by high-fat diet plus STZ), as well as normoglycemic controls

However, the question of whether GLP-1 drugs might indirectly contribute to yeast infection risk requires nuanced consideration

Industry 2 min read Drug withdrawal rebound remains an unmet need in GLP-1R agonist space: GlobalData The rebound effect upon GLP-1R agonists withdrawal needs to be investigated further and new drug developments should aim to mitigate this big limitation and find ways in which GLP-1R agonists could be used as short-term therapies without causing weight regain and cardiometabolic risk reversal